Table 1.
Baseline patient demographics and procedure characteristics
| Characteristics | EH | MVI |
|---|---|---|
| Patients | 70 | 18 |
| Sex (M/F) | 56/14 | 15/3 |
| Mean age | 62 (41–81) | 61 (55–74) |
| BCLC stage 0/A | 70 | 18 |
| Etiology of liver disease | ||
| Hepatitis C | 46 (65.7%) | 8(44.4%) |
| Hepatitis B | 3 (4.3%) | 3 (16.7%) |
| Alcohol abuse | 29 (41.4%) | 8 (44.4%) |
| Hepatitis C + alcohol | 21 (30%) | 5 (27.8%) |
| ECOG 0 | 70 | 18 |
| Treatment naïve | 70 | 18 |
| Mean tumor size (cm) | 3.1 (± 1.2) | 3.1 (± 1.1) |
| Watershed tumors | 10 (14.3%) | 2 (11.1%) |
| AFP > 400 | 5 (7.3%) | 1 (6.6%) |
| Total bilirubin | 1.4 | 1.5 |
| Mean doxorubicin dose (mg) | 81.5 (10–225) | 64 (25–125) |
Data are presented as number (range), number (percentage), or mean (± standard deviation) where appropriate. EH end-hole catheter, MVI microvalve infusion catheter, M male, F female, BCLC Barcelona Clinic Liver Cancer, ECOG Eastern Cooperative Oncology Group, AFP alpha-fetoprotein. Watershed tumor was defined as a tumor located in segment 4a or 4b